Dopamine-receptor families and the treatment of Parkinson's disease

P. J. Bedard, B. Gomez-Mancilla, P. Blanchet, R. Grondin, T. DiPaolo, Sethy, M. F. Piercey, T. N. Chase, R. A. Wise, J. S. Perlmutter, Ranhoksy

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


A series of experiments were performed in the MPTP (n-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine) monkey model of parkinsonism to identify the role of specific dopamine receptors in the therapeutic response and in the production of dyskinesia, one of the main side effects of antiparkinsonian treatment. In the first series of experiments, selective agonists of D1 or D2 receptors were administered to parkinsonian monkeys previously treated with L-dopa that had developed prominent dyskinesia. Both D1 and D2 agonists displayed good antiparkinsonian efficacy, but D1 agonists were much less likely to reproduce the dyskinesia. In the second group of experiments, drug-naive MPTP monkeys were treated chronically with a single dopaminergic agent acting on either the D1- or the D2-receptor family. Both types of agonists, particularly the short-acting D2 agonists administered continuously by minipump, were less dyskinetogenic.

Original languageEnglish
Pages (from-to)S178-S187
JournalClinical Neuropharmacology
Issue numberSUPPL. 1
StatePublished - 1995


  • D- and D-selective agonists
  • Dyskinesia
  • L- Dopa
  • MPTP-induced parkinsonism

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)


Dive into the research topics of 'Dopamine-receptor families and the treatment of Parkinson's disease'. Together they form a unique fingerprint.

Cite this